Second Primary Cancers After Gastric Cancer, and Gastric Cancer as Second Primary Cancer
Authors/Creators
- 1. Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Faculty of Medicine, University of Heidelberg, Heidelberg, Germany. Center for Primary Health Care Research, Lund University, Malmö, Sweden.
- 2. Center for Primary Health Care Research, Lund University, Malmö, Sweden. Department of Family Medicine and Community Health.Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- 3. Center for Primary Health Care Research, Lund University, Malmö, Sweden. Department of Family Medicine and Community Health.Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Center for Community-Based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Matsue, Shimane, Japan.
- 4. Department of Cancer Prevention, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, 310022, People's Republic of China.
- 5. Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Center for Primary Health Care Research, Lund University, Malmö, Sweden. Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany. Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
- 6. Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
Description
Background: Second primary cancers (SPCs) are increasing, which may negatively influence patient survival. Gastric cancer (GC) has poor survival and when it is diagnosed as SPC it is often the cause of death. We wanted to analyze the risk of SPCs after GC and the risk of GC as SPC after any cancer. Such bidirectional analysis is important in relation to fatal cancers because SPCs may be under-reported in the short-term survival period.
Methods: Cancers were obtained from the Swedish Cancer Registry from years 1990 through 2015. Standardized incidence ratios (SIRs) were used to estimate bidirectional relative.
Results: We identified 23,137 GC patients who developed 1042 SPCs (4.5%); 2158 patients had GC as SPC. While the risk for three SPCs was increased after GC, seven first primary cancers were followed by an increased risk of GC as SPC, including esophageal, colorectal, bladder, squamous cell skin and breast cancers and non-Hodgkin lymphoma. Breast cancer, which was followed by a diagnosis of second GC, showed an excess of lobular histology.
Conclusion: Multiple primary cancers in the same individuals may signal genetic predisposition. Accordingly, the association of GC with breast cancer may be related to mutations in the CDH1 gene, and clustering of colorectal, small intestinal and bladder cancers could be related to Lynch syndrome. The third line of findings supports a contribution of immune dysfunction on the increased risk of GC as SPC after skin cancer and non-Hodgkin lymphoma. Early detection of GC in the risk groups could save lives.
Notes
Files
597528.pdf
Files
(1.3 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:74a1f68bd9b33c14c1840adda43abf62
|
1.3 MB | Preview Download |